1. Yaben has been lurking at a low level for five years
From 2017 to 2021, Yaben’s stock price has been fluctuating around 6 yuan at a low level of 20-30% for 5 years. As long as it is horizontal, it is as high as it is vertical!
In the past three years, a super-large main force has lurked in it, and the main force has a high degree of control over the market.
2. Analysis of the sharp rise and fall trend in the past three months
After the market opened on the seventh day of the first lunar month, the main force did not hesitate, hitting the limit at one word, and the limit fell infinitely for one day, and then plummeted for 4 days,* ** fell 44%, falling 44% from the high, which means that it will take another 88% rise to reach the previous high, cruel! It dropped to as low as 14.6 yuan. Panic spread among the Yaben group, and they rushed to flee. Fang Xinxia, ??who cost 22 yuan, sold 113 million yuan and still held more than 90 million yuan. Ge Weidong, who cost 15 yuan, sold 38 million yuan and still held 160 million yuan. From the perspective of chip distribution, most of the profit-making chips at the bottom fled with profits.
On February 11, 2022, Porton announced that it had received a large order of US$681 million from Pfizer. Yaben, which is inextricably linked to Pfizer’s oral drug Paxlovid, the second trading day in February Yaben hit the daily limit 10 minutes after the market opened on the 14th. It continued its upward attack and went into battle lightly. A new high was just around the corner!
This year’s target is 522 yuan to 600 yuan.
3. It’s time for the silent and wealthy Yaben to appear
In the past three months, Yaben has been silent, talking less and doing more. Keep quiet and make a fortune.
The China Securities Regulatory Commission doesn’t ask, don’t tell, and when it does, it doesn’t give an in-depth introduction. It gives people the impression that it is honest and does not stir up trouble or take advantage of hot topics.
Yaben, show your trump card!
4. Review of Yaben’s major events
(1) Composition of Yaben series aircraft carriers
Yaben has six bases, three R&D centers, two A satellite company, two major environmental protection businesses, a subsidiary company, Abino Pharmaceuticals and Health Products Company of the United States, and nearly 20 partners around the world. (For detailed introduction, please see the previous article "Yaben ABA Empire Layout Blueprint")
(2) Purchasing the Caronic Anhydride Patent
In 2011, 500,000 yuan was used to purchase the Caronic Anhydride of Shanghai North Carolina Pharmaceutical Company Production patent, an annual production capacity of 240 tons was built in 2012, used to produce caronic anhydride, an intermediate for the hepatitis C boceprevir drug. Later, because of the serious side effects of this drug, the WHO did not recommend its use. There was no way. In 2014, Yaben changed the production line to produce pesticide intermediates, retaining the annual production capacity of 30 tons of caronic acid anhydride and producing a small amount of boceprevir drug.
(3) Acquisition of Malta’s CDMO subsidiary ACL
On May 16, 2017, it purchased 100% of the equity of Malta’s ACL company for 24.458 million euros (approximately 180 million yuan). After completing the equity transfer, all equity interests in ACL will be obtained. ACL is a well-known first-generation generic drug CDMO company in Europe. It has more than 20 years of CDMO experience and holds US FDA certification.
(4) Establishment of Sun Company A2W
On December 18, 2019, Sun Company A2W was established to produce cannabidiol CBD, with a planned annual production capacity of 700kg. Mass production is expected in 2023.
(5) Satellite company layout
1. Hubei Xiangyang Yuchang Fine Chemical Co., Ltd., Yaben laid out on November 19, 2019, with 18% equity participation.
On January 12, 2022, the carronic acid anhydride project with an annual production capacity of 500 tons was declared;
On January 28, 2022, the intermediate 549 project with an annual production capacity of 300 tons was declared.
2. Liaoning Fuxin Fulongbao Pharmaceutical Technology Co., Ltd. was established by Yaben on March 9, 2020, with a 20% shareholding.
(6) The production line for pesticide intermediates was changed back to the production of caronic anhydride
In September 2021, caronic anhydride was snapped up on the market. Yaben was keenly aware of the business opportunities and immediately after research It will invest 6.9 million yuan in the production line that was converted into pesticide intermediates and return it to the production of caronic anhydride. On November 4, it was announced that Yaben will mass produce 20 tons of caronic anhydride per month.
(7) Application for the 771 patent for advanced medical intermediates
On December 21, 2021, Yaben subsidiary Shanghai Puyi Chemical Technology Co., Ltd. has officially applied for the 771 patent for advanced intermediates< /p>
(8) Application for 50 tons of Palo Verde API
On January 17, 2022, the application for a 50-ton Palo Verde API project was approved.
(9) On February 12, 2022, China urgently approved the import of Pfizer’s oral COVID-19 drug.
6. Yaben, show your trump card! Show your trump card! Ideal production capacity in 2022
1. Carronic anhydride production capacity
241250500=1360 tons
2. Advanced intermediate 771 production capacity
p>
680 tons
3. Pfizer’s oral drug Palo Verde API production capacity
50 tons
4. Pfizer’s first authorized ACL generic drug
Very likely
5. A2W produces hemp CBD
Mass production in 2023
6. Pesticides and intermediates
p>
7. Environmental protection
8. Longevity and health care NMN, AKG